Spironolactone and Hydrochlorothiazide NDC 42292-017

NDC codes

FDA NDC Directory

Product NDC (as listed)42292-017Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42292-0017Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42292-017-20	42292001720	100 BLISTER PACK in 1 CARTON (42292-017-20) / 1 TABLET in 1 BLISTER PACK (42292-017-01)Marketed from May 12, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Spironolactone and Hydrochlorothiazide
Generic name (nonproprietary): spironolactone and hydrochlorothiazide
Active ingredients: Spironolactone — 25 mg/1Hydrochlorothiazide — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Mylan Institutional Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 086513
Marketing start: May 12, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Aldosterone Antagonists (Mechanism)Increased Diuresis (Physiologic effect)Thiazides (Chemical structure)
Identifiers: Product ID 42292-017_3a8771af-a996-d095-e063-6294a90a5cc2SPL ID 3a8771af-a996-d095-e063-6294a90a5cc2SPL set ID f2a4fbc0-650b-440d-9555-c1720fe0fe35RxCUI 198224UNII 27O7W4T232, 0J48LPH2TH
Pharmacologic class: Aldosterone Antagonist; Thiazide Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442292001720 followed by a unit qualifier and the quantity

Package 42292-0017-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 22, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; The treatment of diuretic-induced hypokalemia in patients with conges…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 086513

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 086513
Product	Strength	Form · route	Labeler	Product NDC
Spironolactone and Hydrochlorothiazide	Spironolactone 25 mg/1; Hydrochlorothiazide 25 mg/1	TabletOral	Safecor Health LLC	48433-090
Spironolactone and Hydrochlorothiazide	Spironolactone 25 mg/1; Hydrochlorothiazide 25 mg/1	TabletOral	Mylan Pharmaceuticals Inc.	0378-0403